Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration

RWD, Canadian Real World Evidence, cancer drug, funding, framework

Oncology therapy is becoming more expensive, challenging the affordability and sustainability of drug programs globally. Health technology assessment organizations use clinical trials for drug funding decisions, which may not reflect real-world outcomes. The Canadian Real-world Evidence for Valu…

Jan 7^th • 8 mins read

Rationale, Strengths, and Limitations of Real-World Evidence in Oncology: A Canadian Review and Perspective

real-world evidence; RWE, real-world studies, RWS, oncology, real-world evidence, RWE, randomized controlled trial, RCT

Data obtained from real-world studies have an integral role in evidence-based medicine, serving as an essential source of safety information and a complement to efficacy data from RCTs. RWE is particularly useful for expanding the evidence base to encompass populations of patients who are not well r…

Apr 26^th • 9 mins read

Use of real-world evidence in cancer drug funding decisions in Canada: a qualitative study of stakeholders’ perspectives

RWE, RCT's, Canada, drug funding, Canadian Real-World Evidence, Data

The study emphasizes the need for a cultural shift, enhanced data infrastructure, investment in capacity building, and stakeholder collaboration for effective use of Real-World Evidence (RWE) in drug funding decisions. Cancer drug costs are escalating, with some offering substantial benefit…

Nov 4^th • 12 mins read